EUVIMEDEUVIMED entdecken
Crossref

Photo-Activated PROTACs for Targeted BRD4 Degradation and Synergistic Photodynamic Therapy in Bladder Cancer

Ke Wang, Mingzhu Zhang, Cheng Huang, Jishuang Zhang, Yinan Hua, Xinlu Qin, Yongming Deng, Shaohua Wei iD, Lin Zhou iD

Molecular Pharmaceutics · 02.06.2025 · 22 (6) · 3388-3400

DOI: 10.1021/acs.molpharmaceut.5c00271 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 17.05.2025. Verfasst von Ke Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Chemistry and Materials Science, Jiangsu Key Laboratory of Bio-functional Materials, Jiangsu Collaborative Innovation Centre of Biomedical…. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Photochemotherapy, Cell Cycle Proteins, Photosensitizing Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Priority Academic Program Development of Jiangsu Higher Education Institutions, Nanjing Medical Science and Technique Development Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proteolysis-targeting chimera (PROTAC) drugs rely on the formation of a ternary complex consisting of the target protein, the drug, and a ubiquitin-protein ligase (E3 ubiquitin ligase). However, some cancer patients may not exhibit sufficient expression of both the target protein and the E3 ligase in tumor tissues, leading to potential off-target effects when treated with conventional PROTACs. In this study, we have developed a photoactivated PROTAC strategy that employs the photosensitizer monosubstituted amino phthalocyanine (ZnPc) and the bromine domain protein 4 (BRD4) ligand (JQ1) as core components. A series of highly active compounds were designed and the most effective and safe candidate (ZnPc-O3-JQ1), was identified. Upon activation by light, ZnPc-O3-JQ1 generates reactive oxygen species (ROS) that degrade BRD4. The degradation of BRD4 results in downregulation of hypoxia-inducible factor-1α (HIF-1α), thereby counteracting the treatment resistance induced by tumor hypoxia during photodynamic therapy (PDT). Furthermore, to mitigate oxidative stress caused by ROS, cells upregulate cystine/glutamate antiporter system (Xc- system, SLC7A11) to enhance glutathione (GSH) synthesis. However, downregulation of HIF-1α inhibits GSH synthesis by inhibiting glutamate-cysteine ligase (GCL, the key enzyme in the de novo synthesis of GSH), disrupting the antioxidant defense system. This photo-PROTAC strategy enables a mutually synergistic effect between PDT and PROTAC, providing a new avenue for the design of safer and more efficient PROTAC drugs, photosensitizers, and combination therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsPhotochemotherapyCell Cycle ProteinsPhotosensitizing AgentsTranscription FactorsHumansCell Line, TumorProteolysisAnimalsReactive Oxygen SpeciesMiceIndolesAzepinesIsoindolesTriazolesHypoxia-Inducible Factor 1, alpha SubunitXenograft Model Antitumor AssaysOrganometallic CompoundsFemaleMice, NudeProteolysis Targeting ChimeraBromodomain Containing ProteinsZinc Compounds

Stichwörter der Autor:innen

BRD4HIF-1αphoto-PROTACsphotodynamic therapyphthalocyanine

Substanzen

BRD4 protein, humanReactive Oxygen SpeciesCell Cycle ProteinsPhotosensitizing AgentsTranscription FactorsIndolesAzepinesIsoindolesTriazoles(+)-JQ1 compound

Autor:innen und Institutionen

  • College of Chemistry and Materials Science, Jiangsu Key Laboratory of Bio-functional Materials, Jiangsu Collaborative Innovation Centre of Biomedical Functional Materials, Key Laboratory of Applied Photochemistry, Nanji…
  • Department of Urology, The Affiliated Hospital of Nanjing University Medical School, Institute of Urology, Nanjing Drum Tower Hospital, Nanjing 210008, China.

ORCID-Profile: Shaohua Wei, Lin Zhou

Förderung

  • National Natural Science Foundation of China
  • Priority Academic Program Development of Jiangsu Higher Education Institutions
  • Nanjing Medical Science and Technique Development Foundation
  • Foundation of Jiangsu Collaborative Innovation Centre of Biomedical Functional Materials, Nanjing Normal University

Zitieren

APA

Wang, K., Zhang, M., Huang, C., Zhang, J., Hua, Y., Qin, X., Deng, Y., Wei, S., & Zhou, L. (2025). Photo-Activated PROTACs for Targeted BRD4 Degradation and Synergistic Photodynamic Therapy in Bladder Cancer. Molecular Pharmaceutics, 22(6), 3388-3400. https://doi.org/10.1021/acs.molpharmaceut.5c00271

Vancouver

Wang K, Zhang M, Huang C, Zhang J, Hua Y, Qin X, et al. Photo-Activated PROTACs for Targeted BRD4 Degradation and Synergistic Photodynamic Therapy in Bladder Cancer. Molecular Pharmaceutics. 2025;22(6):3388-3400. doi:10.1021/acs.molpharmaceut.5c00271

BibTeX
@article{Wang2025,
  author = {Wang, Ke and Zhang, Mingzhu and Huang, Cheng and Zhang, Jishuang and Hua, Yinan and Qin, Xinlu and Deng, Yongming and Wei, Shaohua and Zhou, Lin},
  title = {Photo-Activated PROTACs for Targeted BRD4 Degradation and Synergistic Photodynamic Therapy in Bladder Cancer},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  volume = {22},
  number = {6},
  pages = {3388--3400},
  doi = {10.1021/acs.molpharmaceut.5c00271}
}
Kostenlos starten →